Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 2/20 | 0.66 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.66 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.66 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 10/20 | 0.60 |
| ▸ | CA2 | P00918 | 10/20 | 0.60 |
| ▸ | CA5A | P35218 | 10/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 10/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15172850 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL1696817 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL2385301 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL4484995 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL5442172 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL1362019 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL12705857 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL10000728 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL5960692 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL863312 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-12-17 | — | — | US | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| CN-116917291-A | Process for preparing enantiomerically enriched forms of 3- (2-chlorothiazol-5-yl) -8-methyl-7-oxo-6-phenyl-2, 3-dihydrothiazolo [3,2-a ] pyrimidin-4-5-ol salts | 巴斯夫欧洲公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11760722-B2 | Inhibitors of cysteine proteases and methods of use thereof | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-2957558-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-8188077-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | KMT2A 2252/4885F2 4541/4885PRSS1 503/4885 |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | KMT2A 3199/4885F2 3758/4885PRSS1 166/4885 |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | KMT2A 3558/4885F2 3943/4885PRSS1 2760/4885 |
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | KMT2A 3794/4885F2 2343/4885PRSS1 1363/4885 |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | KMT2A 3199/4885F2 3758/4885PRSS1 166/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | KMT2A 134/4885F2 4227/4885PRSS1 2219/4885 |
| US-11760722-B2 | Inhibitors of cysteine proteases and methods of use thereof | SERPINB1, PREP, DNPEP | KMT2A 3938/4885F2 586/4885PRSS1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.